

---

## Press Release

7 May 2019

### **Immunicum AB (publ) Announces Upcoming Conferences in May and June**

Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in May and June.

#### **30<sup>th</sup> Annual Cancer Progress Conference**

Date: May 7 – 8, 2019

Venue: Convene at 32 Old Slip, New York, USA

Participant: Sijme Zeilemaker

#### **14<sup>th</sup> Annual World Advanced Therapies & Regenerative Medicine Congress & Expo 2019**

Date: May 15 – 17, 2019

Presentation Date & Time: May 17 ; 14.30 – 14.50 BST

Venue: Business Design Center, London, UK

Participants: Margareth Jorvid, Sharon Longhurst

#### **RedEye Pre-ASCO Seminar**

Date: May 28, 2019

Presentation Time: 10.30 CEST

Venue: Mäster Samuelsgatan 42, Stockholm, Sweden

Participant: Carlos de Sousa

#### **Great American-China Bio-Partnering Forum**

Date: May 30 – 31, 2019

Presentation Time: 11.00 – 11.20 CDT

Venue: Renaissance Schaumburg Convention Center Hotel, Chicago, USA

Participant: Carlos de Sousa

#### **Sachs Associates 5<sup>th</sup> Annual Immuno-Oncology BD&L and Investment Forum**

Date: May 31, 2019

Presentation Time & Location: 11.10 – 11.30 CDT ; Faulkner, Track B

Panel & Time: Revised Strategies for Advanced Therapeutics Panel ; 13.40 EDT

Venue: Waldorf Astoria Chicago Hotel, Chicago, USA

Participants: Carlos de Sousa, Sijme Zeilemaker

#### **2019 ASCO Annual Meeting**

Date: May 31–June 4, 2019

Venue: McCormick Place, Chicago, USA

Participants: Carlos de Sousa, Peter Suenart, Alex Karlsson-Parra, Sijme Zeilemaker

#### **Småbolagsdagen 2019**

Date: June 3, 2019

Time: 8.00 – 18.00 CEST

Venue: Sheraton Hotel Tegelbacken 6, Stockholm

Participants: Michaela Gertz

#### **FOR MORE INFORMATION, PLEASE CONTACT:**

Carlos de Sousa, CEO, Immunicum

Telephone: +46 8 732 8400

E-mail: [info@immunicum.com](mailto:info@immunicum.com)

---

Michaela Gertz, CFO, Immunicum  
Telephone: +46 70 926 17 75  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

#### **MEDIA RELATIONS**

Gretchen Schweitzer and Joanne Tudorica  
Trophic Communications  
Telephone: +49 172 861 8540  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

#### **U.S. AND INTERNATIONAL INVESTOR RELATIONS**

Thomas Renaud  
Arrowhead Business and Investment Decisions, LLC  
Telephone: +1 212 619-6889 or +1 917 370-5879  
E-mail: [thomas.renaud@arrowheadbid.com](mailto:thomas.renaud@arrowheadbid.com)  
Immunicum abid.co page: [www.abid.co/OMX.IMMU](http://www.abid.co/OMX.IMMU)

#### **SWEDISH INVESTOR RELATIONS**

Jonas Rodny and Carolin Wiken  
Paues Åberg Communications  
Telephone: +46 190 90 51  
E-mail: [jonas.rodny@pauesaberg.se](mailto:jonas.rodny@pauesaberg.se) or [carolin.wiken@pauesaberg.se](mailto:carolin.wiken@pauesaberg.se)

#### **ABOUT IMMUNICUM AB (PUBL)**

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. [www.immunicum.com](http://www.immunicum.com)